UCB Investor
You see, UCB wants to be a world leader when it comes to treating ailments related to the immune and central nervous systems (CNS).
Investment Stage:
Early Stage Venture
Founded Date:
1928-01-01
Estimated Revenue:
$1B to $10B
Total Funding:
202213820.0
Investors Number:
1
Employee Number:
5001-10000
Number Of Exists:
3
Acquisitions Number:
Made Acquisitions
Last Funding Type:
Post-IPO Equity
Industry:
Biotechnology
Headquarters:
Brussels, Brussels Hoofdstedelijk Gewest, Belgium
Funding Status:
IPO
Last Funding Date:
2022-05-24